Ligand Pharmaceuticals and Pfizer have extended their JAK3 research collaboration for another year. Ligand will receive $3.1 million in research payments to continue drug discovery and lead candidate optimization. Under the original agreement, Ligand is entitled to receive as much as $175 million in success-based milestones for the development and commercialization of multiple products. In addition, Ligand will receive royalties on product sales. “We are very pleased to learn that Pfizer has ...